The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

Part of paid clinical trials in Fayetteville, Arkansas.

Sponsor
University of Arkansas, Fayetteville
Study ID
NCT06115603
Phase
PHASE2
Status
Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Cannabigerol — DRUG
    1 mL of 80mg Cannabigerol once during experimental session
  • Placebo — OTHER
    1 mL of placebo once during experimental session

Study Details

The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.

Key Dates

Start date
Dec 14, 2024
Status verified
May 2026
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026

Study Design

Enrollment
76 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Cannabigerol
    1mL of 80mg of Cannabigerol. Cannabigerol is a safe, legal, non-high-inducing cannabinoid obtained from the cannabis plant.
  • Placebo Comparator: Placebo
    1mL of Placebo. Placebo is made in the form of MCT oil.

Primary Outcome Measure

Sustained Attention to Response Task [ Time Frame: 75 minutes post CBG/placebo administration ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of ArkansasFayettevilleArkansas72703
Ellen Leen-Feldner, PhD

Find similar trials in Fayetteville, AR

By condition

Related Studies